{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:10:38Z","timestamp":1790946638449,"version":"4.1.0"},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,8,20]],"date-time":"2012-08-20T00:00:00Z","timestamp":1345420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Purpose:\u2002<\/jats:bold>\n                    To assess the efficacy and safety of once\u2010daily doses of perampanel 8 and 12\u2003mg when added to 1\u20133 concomitantly administered, approved antiepileptic drugs (AEDs) in patients with uncontrolled partial\u2010onset seizures.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    Study 305 was a multicenter, double\u2010blind, placebo\u2010controlled trial in patients aged 12\u2003years and older with ongoing seizures despite prior therapy with at least two AEDs, and currently receiving 1\u20133 AEDs. Equal randomization to once\u2010daily oral perampanel 8 or 12\u2003mg, or placebo was performed. Patients entered a 19\u2010week double\u2010blind treatment phase comprising a 6\u2010week titration period, with weekly 2\u2010mg dose increments, followed by a 13\u2010week maintenance period. Primary efficacy end points were the responder rate (proportion of patients who had a \u226550% reduction in seizure frequency during treatment per 28\u2003days relative to baseline), and the percent change in seizure frequency per 28\u2003days relative to pre\u2010perampanel baseline. A secondary end point was percent change in the frequency of complex partial plus secondarily generalized seizures. Adverse events (AEs) were monitored throughout the study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Key Findings:\u2002<\/jats:bold>\n                    Three hundred eighty\u2010six patients were randomized and treated with study medication. Of these, 321 patients completed the study. The 50% responder rates (intent\u2010to\u2010treat analysis) were 14.7%, 33.3%, and 33.9%, respectively, for placebo, perampanel 8\u2003mg, and perampanel 12\u2003mg, with significant improvements over placebo for both perampanel 8\u2003mg (p\u2003=\u20030.002) and 12\u2003mg (p\u2003&lt;\u20030.001). The median percent change from baseline in seizure frequency per 28\u2003days (intent\u2010to\u2010treat analysis) was \u22129.7%, \u221230.5%, and \u221217.6% for placebo, 8 mg, and 12\u2003mg, respectively, with significant reductions compared with placebo for both 8\u2003mg (p\u2003&lt;\u20030.001) and 12\u2003mg (p\u2003=\u20030.011). For complex partial seizures plus partial seizures that secondarily generalized, the median percent change in frequency was \u221232.7% (8\u2003mg), \u221221.9 (12\u2003mg), and \u22128.1% (placebo), with significant reductions for both 8\u2003mg (p\u2003&lt;\u20030.001) and 12\u2003mg (p\u2003=\u20030.005). The most frequent (occurring in \u226510% of patients in any treatment group) treatment\u2010emergent AEs were dizziness, somnolence, fatigue, and headache, with an apparent dose effect suggested for all except headache.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Significance:\u2002<\/jats:bold>\n                    This phase III trial demonstrated that adjunctive treatment with once\u2010daily perampanel at 8 mg and 12\u2003mg was effective in improving seizure control in patients 12\u2003years and older with refractory partial\u2010onset seizures. These study results also demonstrated that once\u2010daily doses of 8 mg and 12\u2003mg were safe and acceptably tolerated in this study. Perampanel demonstrated a favorable risk\/benefit ratio in this population.\n                  <\/jats:p>","DOI":"10.1111\/j.1528-1167.2012.03638.x","type":"journal-article","created":{"date-parts":[[2012,8,20]],"date-time":"2012-08-20T11:40:15Z","timestamp":1345462815000},"page":"117-125","source":"Crossref","is-referenced-by-count":375,"title":["Evaluation of adjunctive perampanel in patients with refractory partial\u2010onset seizures: Results of randomized global phase III study 305"],"prefix":"10.1111","volume":"54","author":[{"given":"Jacqueline A.","family":"French","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard J.","family":"Steinhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Squillacote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Laurenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,8,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02522.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.11.1680"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182194bd3"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182635735"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01136.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01951.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03109.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2011.01588.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318254473a"},{"issue":"1","key":"e_1_2_7_12_1","article-title":"Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials","volume":"12","author":"Laurenza A","year":"2012","journal-title":"Epilepsy Curr"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7511-11.2.56"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2012.03638.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2012.03638.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T07:16:52Z","timestamp":1698650212000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2012.03638.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,20]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1528-1167.2012.03638.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03638.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.720651588.793506024","asserted-by":"object"}]},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,20]]}}}